<DOC>
	<DOCNO>NCT00588380</DOCNO>
	<brief_summary>Glucagon-like Peptide-1 ( GLP-1 ) important incretin hormone act powerful insulin secretagogue . Defects GLP-1 synthesis secretion think part pathogenesis type 2 diabetes . Furthermore GLP-1 base therapy important part therapeutic armamentarium treatment type 2 diabetes . The GLP-1 receptor ( GLP1R ) principal site action GLP-1 GLP-1 receptor agonist like exenatide liraglutide . The gene cod receptor , GLP1R , highly polymorphic contains numerous non-synonymous Single Nucleotide Polymorphisms ( nsSNPs ) could potentially alter response endogenous exogenous GLP-1 GLP-1R agonist . Indeed vitro data support concept . We propose utilize hyperglycemic clamp test insulin secretory response infuse GLP-1 healthy volunteer determine effect genetic variation GLP1R response GLP-1 .</brief_summary>
	<brief_title>GLP1R Polymorphisms Response GLP1</brief_title>
	<detailed_description />
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Aged 1840 fast glucose concentration le 95 mg/dl . Individuals BMI &lt; 19 &gt; 40 kg/m^2 active systemic illness medication alter gastric emptying , insulin secretion &amp; action history abdominal surgery ( appendectomy tubal ligation ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>Insulin Secretion</keyword>
</DOC>